Where does Sequent Medical, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sequent Medical, Inc. ranks #10,450 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sequent Medical, Inc. hold?

Sequent Medical, Inc. holds 30 US utility patents granted between 2015 and 2023, spanning 5 technology areas.

What is Sequent Medical, Inc.'s Innovation Score?

Sequent Medical, Inc. has an Innovation Score of 34.5 out of 100 (48th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sequent Medical, Inc. focus on?

Sequent Medical, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 24 patents. Grants appear in 5 CPC subclasses total.

Is Sequent Medical, Inc.'s patent grant rate increasing or decreasing?

Sequent Medical, Inc.'s recent grant velocity is -24% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Sequent Medical, Inc.'s patents?

Sequent Medical, Inc.'s patents average 19.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sequent Medical, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Sequent Medical, Inc.

USPTO PatentsView assignee record - 30 granted patents across 5 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sequent ranks #10,450 of 49,997 tracked US assignees by granted-patent volume, with 30 patents across 5 technology areas.

#10,450
of 49,997 US assignees by volume: 48th percentile
by Innovation Score (34.5/100): 19.5
avg claims per patent: -24%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10450 · US Corporation #10,450 · 30 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 30 grants
UPPER-Q #10,450/49,997
PHOTO-FINISH SanBio
CPC-NARROW A61B · 5 areas
INNOV-THIN 34.5/100
CLAIMS-RICH 19.5 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -24% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: SanBio, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Kompan A/S · near

34
Laboratorios DEL DR… · near

34
Oculeve · near

34
Sequent Medical · this assignee

34
TecPharma Licensing · near

34
3D Lighting… · lowest

7

What this shows Sequent's Innovation Score is 34.5/100 (48th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Sequent's grants concentrate

Sequent Medical, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 80% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2021 (6 grants) versus a trough of 2 in 2015. By volume, Sequent sits between Suven Life Sciences Limited and SpineSmith Partners, L.P..

Sequent's three-year grant acceleration

Sequent Medical, Inc. shows 5 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Suven Life Scienc…

30
Sanbio

30
Sensible Medical…

30
Sentry Solutions…

30
Shenzhen Breo Tec…

30
Siemens Österreich

30
Skywave Networks

30
Spinesmith Partne…

30
Sequent Medical ◀

30

What this shows Sequent holds 30 patents at rank #10,460, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sequent

By rank, the assignees closest to #10,460 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Sequent's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Sequent, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (34 here).

Kompan A/S 34 Oculeve, Inc. 34 Laboratorios DEL DR. Esteve S.A. 34 TecPharma Licensing AG 34

Sequent's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 48th percentile higher than 48% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Sequent Medical, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	6.7%
2016	5	16.7%
2017	3	10.0%
2018	4	13.3%
2019	3	10.0%
2020	2	6.7%
2021	6	20.0%
2022	3	10.0%
2023	2	6.7%

Which technologies does Sequent Medical, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 24

D10B - Indexing Scheme Associated With Sublasses OF Section D, Relating TO Textiles 6

D04C - Braiding OR Manufacture OF Lace, Including Bobbin-net OR Carbonised LACE; Braiding MACHINES; BRAID; Lace 6

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 4

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

Top 5 of 5 technology areas

Where it ranks

Overall rank by patents

#10,450

of 49,997 tracked assignees

Innovation Score

34.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Sequent Medical, Inc.'s patent record in context - here's where to go next.

Sequent Medical, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 80% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #10,450 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Sequent Medical, Inc. against Suven Life Sciences Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.